IntelGenx gets bupropion patent in U.S.

IntelGenx (TSX-V:IGX) has received a U.S. patent  for CPI-300, a new formulation of bupropion hydrochloride, the active ingredient in Wellbutrin XL, covering the formulation of pharmaceutical tablets containing sustained-release granules of bupropion HCl distributed in a sustained-release matrix. “The successful issuance of this patent provides formidable intellectual property protection for CPI-300 and further strengthens our [...]